Herb Greenberg: Serious about Osiris?

Herb Greenberg: Serious about Osiris?: "Osiris' (osir) stock got a boost after stem cell biotech company presented positive data on a heart drug it's working on. Merely a Phase 1 trial? No worries; it's the story that counts. Stock opened up 20% until investors sobered; as I write this it's up about 9%. (Isn't this the same company whose stock got clobbered several weeks ago after Phase 1/2 trials for a knee repair drug didn't go so well? Indeed it is.) Former bull Eun Yang, of Jefferies, who downgraded the stock after the recent disappointment, didn't change his mind on the heels of the early heart drug results. He says he wants to see detailed data. The big hype and hope for this company will be the results of Phase 3 trials for its graft-vs.-host drug. According to Yang, however, that's already in the stock. (Not that positive results, in a story-driven market such as this, won't keep it from going higher at the time.)"